首页> 外文OA文献 >Assessing airways deposition, physiology and pharmacokinetics of monodisperse aerosols in obstructive lung disease
【2h】

Assessing airways deposition, physiology and pharmacokinetics of monodisperse aerosols in obstructive lung disease

机译:评估阻塞性肺病中单分散气溶胶的气道沉积,生理学和药代动力学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inhaled medication is standard therapy in asthma and COPD. However the amount of drug reaching the lung is influenced by several factors including aerosol particle size and upper airway morphology. While smaller sized aerosol particles may be transported to the small airways there is still a need to examine the systemic risk and efficacy associated with small particle aerosols. On one hand small particles can be transported to the lung periphery (small airways) where they can reduce small airways dysfunction. On the other hand small particles can increase plasma concentrations of the drug worsening systemic side effects. Aerosol particle size determines deposition throughout the whole of the respiratory tract including the upper airway and by altering aerosol delivery characteristics it is possible to avoid deposition in the upper airway. This thesis set out to investigate how to improve drug deposition in the lung by controlling aerosol delivery characteristics mainly particle size and flow rate and investigate how the filtering effects of the upper airway can be overcome. udThe specific aims of this thesis were:udTo quantify aerosol deposition in the upper airway both in vitro and in vivo with the hope of using in vitro techniques to predict what happens in vivo. udExplore how aerosol particle size effects lung deposition and pulmonary bioavailability through pharmacokinetics. udInvestigate and evaluate novel tests of small and large airways function and see if these can detect physiological improvement following inhalation of small (1.5 µm) particles and large (6 µm) particles. udIn vitro tests on upper airway models somewhat predicted what happens in vivo. The increasing effect of both particle size and flow rate was shown to increase upper airway deposition. Tests of respiratory function and inflammation demonstrated greater between test variability than routine tests of lung function and warrant further evaluation. Improvements in small and large airway function were not associated with the deposition of small and large aerosol particles following one off dosing of an inhaled corticosteroid fluticasone propionate and a link between these tests and aerosol particle size warrants further investigation.
机译:吸入药物是哮喘和COPD的标准治疗方法。但是,到达肺部的药物量受多种因素影响,包括气溶胶粒径和上呼吸道形态。尽管较小尺寸的气溶胶颗粒可能会被输送到小气道,但仍然需要检查与小颗粒气溶胶相关的系统性风险和功效。一方面,小颗粒可以被运输到肺部周围(小气道),在那里它们可以减少小气道功能障碍。另一方面,小颗粒会增加药物的血浆浓度,使全身性副作用恶化。气溶胶的粒径决定了包括上呼吸道在内的整个呼吸道的沉积,并且通过改变气溶胶的输送特性,可以避免在上呼吸道中的沉积。本文着手研究如何通过控制气溶胶的输送特性(主要是粒径和流速)来改善药物在肺中的沉积,并探讨如何克服上呼吸道的过滤作用。 ud本论文的具体目的是: ud为了定量研究上呼吸道在体内和体外的气溶胶沉积,希望使用体外技术来预测体内发生的事情。 ud探索气雾剂粒径如何通过药代动力学影响肺部沉积和肺生物利用度。 ud研究并评估新的小气道和大气道功能测试,看看这些测试能否在吸入小颗粒(1.5 µm)和大颗粒(6 µm)后检测出生理改善。 ud在上呼吸道模型上进行的体外试验多少可以预测体内发生的情况。粒径和流速的增加效果均显示出增加了上呼吸道的沉积。呼吸功能和炎症测试之间的变异性比常规肺功能测试高,值得进一步评估。吸入皮质类固醇氟替卡松丙酸酯一次给药后,大小型气道功能的改善与大小型气溶胶粒子的沉积无关,这些试验与气溶胶粒径之间的联系值得进一步研究。

著录项

  • 作者

    Kalsi Harpal;

  • 作者单位
  • 年度 2016
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号